Anavex Life Sciences Corp. (AVXL)

Market Cap	834.16M
Revenue (ttm)	n/a
Net Income (ttm)	-43.00M
Shares Out	84.82M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,681
Open	9.83
Previous Close	9.70
Day's Range	9.80 - 10.03
52-Week Range	3.25 - 14.44
Beta	0.70
Analysts	Strong Buy
Price Target	44.00 (+347.38%)
Earnings Date	Feb 10, 2025

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, wh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 42
• Stock Exchange: NASDAQ
• Ticker Symbol: AVXL
• Website: https://www.anavex.com

Analyst Forecast

According to 2 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is $44.0, which is an increase of 347.38% from the latest price.

Price Target

$44.0

(347.38% upside)

Analyst Consensus: Strong Buy